LONDON, March 27 (Reuters) - Two international medical
humanitarian organisations said on Monday they had challenged
the patent on Gilead Sciences' hepatitis C drug
sofosbuvir at the European Patent Office in order to increase
access to the treatment.
Read more
No comments:
Post a Comment